Fortress Biotech Inc

NASDAQ:FBIO   3:59:50 PM EDT
3.00
-0.04 (-1.32%)
Products, Regulatory

Fortress Biotech And Cyprium Therapeutics Announce Positive Clinical Data For Cutx-101, Copper Histidinate

Published: 10/08/2021 12:56 GMT
Fortress Biotech Inc (FBIO) - Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for Cutx-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition.
Cyprium Therapeutics - Overall Survival Significantly Improved in Patients Treated With Cutx-101.
Cyprium Therapeutics - Rolling Submission of New Drug Application to FDA for Cutx-101 Planned to Begin in Q4 of 2021.